Patient Reported Outcomes (PRO) and Tolerability of Capivasertib (Capi) plus Abiraterone (Abi) versus Placebo (Pbo) plus Abi in Patients (Pts) with PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): CAPItello-281
Loading...
Date
2026-03-01
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams & Wilkins
Open Access Color
OpenAIRE Downloads
OpenAIRE Views
Abstract
Description
Keywords
Fields of Science
Citation
WoS Q
Scopus Q
Source
ASCO Genitourinary Cancers Symposium -- FEB 26-28, 2026 -- San Francisco, CA
Volume
44
Issue
7_SUPPL
Start Page
End Page
